Products & Services


The main focus of SIMABS is to manufacture therapeutic monoclonal antibodies with an integrated continuous manufacturing platform that enables to make the products at a small scale and cost effective. This combination makes the value proposition of SIMABS unique.

With this new manufacturing platform, SIMABS will target two market segments:

  • Companies that produce therapeutic biosimilars at a smaller scale in a cost-efficient way.
  • Small clinical batches for innovative biopharmaceutical companies that want to outsource their GMP production.

SIMABS will provide services with regards to project management and technology transfer for the manufacturing of monoclonal antibodies to these companies.